Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease

Journal of the American Academy of Dermatology

Volumn 42, Issue 3, 2000, Pages 480-489

  Walsh, Patrick ^a   Gibbs, Peter ^a   Gonzalez, René ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Box E 190   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CANCER VAX; CARMUSTINE; CISPLATIN; DACARBAZINE; GANGLIOSIDE GM2; INTERFERON; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MELACINE; PHOSPHORYL LIPID A; QS 21; TAMOXIFEN; UNCLASSIFIED DRUG; VINBLASTINE;

CANCER MORTALITY; CLINICAL FEATURE; DRUG EFFICACY; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

EID: 0033910314     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(00)90223-8     Document Type: Article

References (88)

1. Handis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Johnson TM, Dolan OM, Hamilton TA, Lu MC, Swanson NA, Lowe L. Clinical and histologic trends of melanoma. J Am Acad Dermatol 1998;38:681-6.
3. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol 1998;38:669-80.
4. Carr I. Lymphatic metastasis. Cancer Metastasis Rev 1983;22: 307-17.
5. del Regato JA. Pathways of metastatic spread of malignant tumors. Semin Oncol 1977;4:33-8.
6. Fidler IJ. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 1973;9:223-7.
7. Balch CM, Cascinelli N, Drzewiecki KT, Eldh J, MacKie RM, McCarthy WH, et al. A comparison of prognostic factors worldwide. In: Balch CM, Milton GW, Soong S, Houghton AN, Sober AJ, editors. Cutaneous melanoma. Philadelphia: JB Lippincott; 1992. p. 196.
8. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697-705.
9. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977;297:627-30.
10. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
11. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Stage I melanoma of the limbs: immediate versus delayed node dissection. Tumori 1980;66:373-96.
12. Balch CM, Soong S-J, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-63; discussion 263-6.
13. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
14. Morton DL, Wen DR, Cochran AJ. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy or "watch and wait." Surg Oncol Clin North Am 1992;1:247.
15. Reintgen DS, Curse CW, Wells K, Berman C, Fenske N, Glass F, et al. An orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
16. Ross MI, Reintgen DS, Balch CM. Selective lymphadenectomy: emerging role of lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993;9:213-23.
17. Ross MI, Reintgen DS. Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases. Eur J Cancer 1998;34(Suppl):S7-11.
18. Krag DN, Meijer SF, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, el al. Minimal-access surgery for slaging of melanoma. Arch Surg 1995;130:654-8.
19. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
20. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
21. Wang X, Heller R, Van Voorhis N, Curse CW, Glass F, Fenske N, et al. Detection of submicroscopic metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-74.
22. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-5.
23. Singletary SE, Byers RM, Shallenberger R, McBride CM, Guinee VF. Prognostic factors in patients with regional cervical nodal metastases from cutaneous malignant melanoma. Am J Surg 1986;152:371-5.
24. Balm AJ, Kroon BB, de Boer JB, Israels SP, Jonk A, Mooi WJ, et al. Report of a symposium on: diagnosis and treatment of cutaneous head and neck melanoma. Eur J Surg Oncol 1994;20:112-4.
25. O'Brien CJ, Gianoutsos MP, Morgan MJ. Neck dissection for cutaneous malignant melanoma. World J Surg 1992;6:222-6.
26. Pearlman NW, Robinson WA, Dreiling LK, McIntyre RC Jr, Gonzales R. Modified ilioinguinal node dissections for metastatic melanoma. Am J Surg 1995;170:647-50.
27. Buzaid AC, Tinoco LA, Jendiroba D, Tu ZN, Lee JJ, Legha SS, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995;13:2361-8.
28. Stadelmann WK, Rapaport DP, Soong S-J, Reintgen DS, Buzaid AC, Balch CM. Prognostic clinical and pathologic features. In: Balch CM, Houghton AN, Sober AJ, Soong S, editors. Cutaneous melanoma. 3rd ed. St Louis: Quality Medical Publishing; 1998. p. 26.
29. Paterson AH, Willans DJ, Jerry LM, Hanson J, McPherson TA. Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J 1984;131:744-8.
30. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913-6.
31. Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA. Corynebacterium parvum versus bacille Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 1991;9:1151-6.
32. Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med 1980;303:1143-7.
33. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991;9: 736-40.
34. Lejeune FJ, Macher E, Kleeberg U, Rumke P, Prade M, Thomas D, Susic S. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin: a phase III adjuvant study (EORTC protocol 18761). Eur J Cancer 1988;24(Suppl):S81-90.
35. Livingston P, Sznol M. Vaccine therapy. In: Balch CM, Houghton AN, Sober AJ, Soong S, editors. Cutaneous melanoma. 3rd ed. St Louis: Quality Medical Publishing; 1998. p. 437-50.
36. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK. Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles & practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 1947-94.
37. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-83.
38. Cascinelli N, Bufalino R, Morabito A, MacKie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994;343:913-4.
39. Kirkwood JM, Ibrahim J, Sondak V, et al. Role of high-dose IFN in high-risk melanoma: preliminary results of the E1690/S9111/ C9190 US intergroup postoperative adjuvant trial of high and low-dose IFN2b (HDI and LDI) in resected high-risk primary or regionally lymph node metastatic melanoma in relation to 10-year updated results of E1684. November 1998. http:// 207.121.155/NCI_CANCER_TRIALS/zones/trialinfo
40. Ollila DW, Kelley MC, Gammon G, Morton DL. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin Surg Oncol 1998;14:328-36.
41. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34-42.
42. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
43. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
44. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
45. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162-9.
46. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
47. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996;156:238-45.
48. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996;156:3357-65.
49. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-92.
50. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507-29.
51. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
52. Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994;54:3342-5.
53. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
54. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25:623-35.
55. Mitchell MS, Von Eschen KB. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma [abstract]. Proc Am Soc Clin Oncol 1997;33:1778A.
56. Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Maguire HC Jr. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 1998;5:646-53.
57. Livingston P. Ganglioside vaccines with emphasis on GM2. Semin Oncol 1998;25:636-45.
58. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage II melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
59. Schultz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Abeles G, Bystryn JC. Effect of DETOX as an adjuvant for melanoma vaccines. Vaccine 1995;13:503-8.
60. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998,48:6-29.
61. Balch CM, Soong S-J, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1:126-34.
62. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;91:193-201.
63. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic melanoma: a multivariate analysis. Cancer 1993,72:3091-8.
64. Wornom IL, Smith JW, Soon SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 1986;204:181-5.
65. Overett TK, Shiu MH. Surgical treatment of distant metastatic melanoma: indications and results. Cancer 1985;56:1222-30.
66. Wong JH, Skinner KA, Kim KA, Foshag LJ, Morton DL. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993;113:389-94.
67. Fell DA, Leavens ME, McBride CM. Surgical versus non-surgical management of metastatic melanoma of the brain. Neurosurgery 1980;7:238-42.
68. Ang KK, Geara FB, Byers RM, Peters LJ. Radiotherapy for melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong S, editors. Cutaneous melanoma. 3rd ed. St Louis: Quality Medical Publishing; 1998. p. 389-403.
69. Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Balch CM, Houghton AN, Milton GW, Soong S, Houghton AN, Sober AJ, editors. Cutaneous melanoma. Philadelphia: JB Lippincott; 1992. p. 499.
70. Hill GJ Jr, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy. Cancer 1984;53:1299-305.
71. Anderson C, Buzaid A, Legha S. Systemic treatment for advanced cutaneous melanoma. Oncology 1995;9:1149-58.
72. Del Prete S, Maurer L, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984;68:1403-5.
73. McClay EF, Mastrangelo M, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987;71:465-9.
74. McClay EF, Mastrangelo M, Sprandio J, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989;63:1292-5.
75. Saxman SB, Meyers M, Chapman PB, Destro AN, Panageas KS, Begg CB. A Phase III randomized trial of DTIC, Cispiatin, BCNU and Tamoxifen versus DTIC alone in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1999;18:2068a.
76. Atkins MB. Interleukin-2 in metastatic melanoma:establishing a role. Cancer J Sci Am 1997:3(Suppl):S7-8.
77. Rosenberg SA, Keynote address: perspectives on the use of interleukin-2 in cancer treatment. Cancer J Sci Am 1997; 3(Suppl):S2-6.
78. Demchak P, Mier J, Robert N, Obrien K, Gould JA, Atkins MB. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991;9:1821-30.
79. Khayat D, Borel C, Tourani JM, Benhammonda A, Antoine E, Rixe O, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alpha-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-80.
80. Flaherty L, Robinson W, Redman B, Gonzalez R, Martino S, Kraut M, et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic melanoma. Cancer 1993;71:3520-5.
81. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, et al. Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-60.
82. Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastic melanoma: the University of Texas M. D. Anderson Cancer Center experience. Cancer J Sci Am 1997;3(Suppl):S9-15.
83. Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999;17:651-7.
84. Keilholz U, Stoter G, Punt CJ, Scheinbenbogen C, Lejeune F, Eggermont AM. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am 1997;3(Suppl):S22-8.
85. Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 1997;3(Suppl):S29-34.
86. Gibbs P, Ianucci A, O'Driscoll M, Becker M, Allen J, Williams P, et al. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res In press.
87. Rosenberg SA, Yang JC, Schwartzentruber J, Hwu P, Marincola F, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-75.
88. Gibbs P, Anderson C, Pearlman N, Becker M, McDowell K, Gonzalez R. Neoadjuvant biochemotherapy for stage III and resectable stage IV malignant melanoma (MM) [abstract]. Presented at the 14th Annual Scientific Meeting of the Society for Biological Therapy, Boston, Mass, Oct 27-30, 1999.